# TABLE OF CONTENTS

## HIGHLIGHTS

- **453** Selected Articles from This Issue

## REVIEW

- **455** Salting the Soil: Targeting the Microenvironment of Brain Metastases
  - Ethan S. Srinivasan, Aaron C. Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M. Ashley, Peter E. Fecci, and Mustafa Khasraw

## SMALL MOLECULE THERAPEUTICS

- **467** Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
  - Aaron Balog, Tai-an Lin, Derrick Maley, Johnni Gullo-Brown, Enzo Hamza Kandoussi, Jianing Zeng, and John T. Hunt

- **477** A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers
  - Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Xiaixia Liu, Cheng-Hsin Wei, Jason Roszik, Adam S. Kittai, Alexey V. Danilov, Xiaoshan Zhang, Bingliang Fang, Jing Wang, John V. Heymach, Liliya Tyutyunyk-Massey, Sarah J. Freemantle, Jonathan M. Kurie, Xi Liu, and Ethan Dmitrovsky

- **490** Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
  - Geun Taek Lee, Naoya Nagaya, Jenny Desantis, Kiran Madura, Hatem E. Sabaawy, Wun-Jae Kim, Roy J. Vaz, Gabriele Cruciani, and Yared Hailemichael

- **500** The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
  - Sruthy Varghese, Snigdha Pramanik, Leila J. Williams, Hannah R. Hodges, Courtney W. Hudgens, Grant M. Fischer, Catherine K. Luo, Barbara Knighton, Lin Tan, Philip L. Lorenzi, Andrew L. Mackinnon, Jennifer L. McQuade, Yared Hailemichael, Jason Roszik, Weiyi Peng, and Y.N. Vashisht Gopal

## LARGE MOLECULE THERAPEUTICS

- **512** Immunotherapy with Immuncytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX
  - Jacopo Millul, Christiane Krudewig, Aureliano Zana, Sheila Dakhel Plaza, Emanuele Puca, Alessandra Villa, Dario Neri, and Samuele Cazzamalli

- **523** Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
  - Nuruddeen D. Lewis, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Tong Zi, Ke Xu, Kevin Dooley, Su Chul Jang, Bryan Choi, Adam Boutin, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Michael Doherty, Leonid Gaidukov, Scott Estes, Kyriakos D. Economides, Douglas E. Williams, and Sriram Sathyanarayanan

- **535** ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium
  - Pooja Hingorani, Michael E. Roth, Yifei Wang, Wendong Zhang, Jonathan B. Gill, Douglas J. Harrison, Beverly Teicher, Stephen Erickson, Gregory Gatto, Malcolm A. Smith, Edward A. Kolb, and Richard Gorlick

- **541** Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
  - Shenlan Mao, Raghothama Chaerkady, Wen Yu, Gina D’Angelo, Andrew Garcia, Hong Chen, Allison M. Barrett, Sandrina Phipps, Ryan Fleming, Sonja Hess, Jens-Oliver Koopmann, Nazzareno Dimasi, Susan Wilson, Kathryn Pugh, Kimberly Cook, Lake A. Masterson, Changshou Gao, Herren Wu, Ronald Herbst, Philip W. Howard, David A. Tice, Mark Cobbold, and Jay Harper
TABLE OF CONTENTS

553  Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
William H. Gmeiner, Anthony Dominijanni, Alex O. Haber, Lais P. Ghiraldeli, David L. Caudell, Ralph D’Agostino Jr, Boris C. Pasche, Thomas L. Smith, Zhiyong Deng, Sezgin Kiren, Chinnadurai Mani, Komaraiah Palle, and Jonathan R. Brody

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

564  Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Marika K.A. Koivu, Deepankar Chakroborty, Mahlet Z. Tamirat, Mark S. Johnson, Kari J. Kurppa, and Klaus Elenius

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

577  Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells
Yida Zhang, Lile He, Ananthan Sadagopan, Tao Ma, Gianpietro Dotti, Yufeng Wang, Hui Zheng, Xin Gao, Dian Wang, Albert B. DeLeo, Song Fan, Ruochuan Sun, Ling Yu, Lijuan Zhang, Gongxian Wang, Soldano Ferrone, and Xinhui Wang

589  Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors
Amy Kwan, Natalie Winder, Emer Atkinson, Haider Al-Janabi, Richard J. Allen, Russell Hughes, Mohammed Moamin, Rikah Louie, Dhanayaj Evans, Matthew Hutchinson, Drew Capper, Katie Cox, Joshua Handley, Adam Wilshaw, Taewoo Kim, Simon J. Tazzymansan, Sanjay Srivastava, Penelope Ottevell, Jayakumar Vadakekolathu, Graham Pockley, Claire E. Lewis, Janet E. Brown, Sarah J. Danson, Joe Conner, and Munitta Muthana

602  Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma
Brandon M. Roane, Selene Meza-Perez, Ashwini A. Katre, Whitney N. Goldsberry, Troy D. Randall, Lyse A. Norian, Michael J. Birrer, and Rebecca C. Arend

612  The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells
Rupesh Shrestha, Kumaravel Mohankumar, Un-ho Jin, Gregory Martin, and Stephen Safe

ABOUT THE COVER
Photomicrographic image of a tumor invasive margin from a syngeneic tumor model (MC38) stained with multiplex immunofluorescence to identify macrophages (F4/80⁺; Red) in the tumor microenvironment. Polarization state of these macrophages was determined using inducible nitric oxide synthase (iNOS; Green), a marker for M1 polarization, and arginase I (Arg1; Cyan) a marker for M2 polarization. In the tumor margins, 152-fold increase in M1 macrophages were observed with exoIL-12 treatment. These studies provide evidence that exoIL-12 was significantly more potent than rIL12 and enabled systemic anti-tumor immunity by facilitating prolonged local pharmacology and undetectable systemic exposure. The improved therapeutic index achieved in pre-clinical models support further clinical investigation of this powerful cytokine. Read the full article on p. 523.